Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 358-367 , March 2010

Outcome of Transplantation for Myelofibrosis

  • Karen K. Ballen

      Affiliations

    • Massachusetts General Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Karen K Ballen, MD, Division of Hematology/Oncology, Massachusetts General Hospital, 0 Emerson, Suite 118, Boston, Massachusetts, 02114.
    • ,
  • Smriti Shrestha

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Kathleen A. Sobocinski

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Mei-Jie Zhang

      Affiliations

    • Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Asad Bashey

      Affiliations

    • The Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia
    • ,
  • Brian J. Bolwell

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Francisco Cervantes

      Affiliations

    • Hospital Clinic, IDIBAPS, Barcelona, Spain
    • ,
  • Steven M. Devine

      Affiliations

    • The Ohio State University Medical Center, Columbus, Ohio
    • ,
  • Robert Peter Gale

      Affiliations

    • Celgene Corporation, Summit, New Jersey
    • ,
  • Vikas Gupta

      Affiliations

    • Princess Margaret Hospital, Toronto, Canada
    • ,
  • Theresa E. Hahn

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • William J. Hogan

      Affiliations

    • Mayo Clinic Rochester, Rochester, Minnesota
    • ,
  • Nicolaus Kröger

      Affiliations

    • University Hospital Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Mark R. Litzow

      Affiliations

    • Mayo Clinic Rochester, Rochester, Minnesota
    • ,
  • David I. Marks

      Affiliations

    • United Bristol Healthcare, Bristol, United Kingdom
    • ,
  • Richard T. Maziarz

      Affiliations

    • Oregon Health and Science University, Portland, Oregon
    • ,
  • Philip L. McCarthy

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Gary Schiller

      Affiliations

    • University of California at Los Angeles, Los Angeles, California
    • ,
  • Harry C. Schouten

      Affiliations

    • University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Vivek Roy

      Affiliations

    • Mayo Clinic Jacksonville, Jacksonville, Florida
    • ,
  • Peter H. Wiernik

      Affiliations

    • New York Medical College and Montefiore–North Division, Bronx, New York
    • ,
  • Mary M. Horowitz

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Sergio A. Giralt

      Affiliations

    • M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Mukta Arora

      Affiliations

    • University of Minnesota Medical Center, Minneapolis, Minnesota

Received 10 July 2009 ,Accepted 22 October 2009.

  • Image Result

    Cumulative incidence of nonrelapse mortality after receiving allogeneic HCT by donor type for myelofibrosis reported to the CIBMTR between 1989 and 2002.

    Cumulative incidence of nonrelapse mortality after receiving allogeneic HCT by donor type for myelofibrosis reported to the CIBMTR between 1989 and 2002.

  • Image Result

    Cumulative incidence of relapse after receiving allogeneic HCT by donor type for myelofibrosis reported to the CIBMTR between 1989 and 2002.

    Cumulative incidence of relapse after receiving allogeneic HCT by donor type for myelofibrosis reported to the CIBMTR between 1989 and 2002.

  • Image Result

    Survival probability of adult patients receiving allogenic transplantation (HLA identical sibling donor and unrelated donor) for myelofibrosis reported to the CIBMTR between 1989 and 2002.

    Survival probability of adult patients receiving allogenic transplantation (HLA identical sibling donor and unrelated donor) for myelofibrosis reported to the CIBMTR between 1989 and 2002.

  • Image Result

    DFS probability of adult patients receiving HLA-identical sibling HCT by different risk groups for myelofibrosis reported to the CIBMTR between 1989 and 2002.

    DFS probability of adult patients receiving HLA-identical sibling HCT by different risk groups for myelofibrosis reported to the CIBMTR between 1989 and 2002.

  • Image Result

    Survival probability of adult patients receiving unrelated donor allogeneic HCT by different risk groups for myelofibrosis reported to the CIBMTR between 1989 and 2002.

    Survival probability of adult patients receiving unrelated donor allogeneic HCT by different risk groups for myelofibrosis reported to the CIBMTR between 1989 and 2002.

 Financial disclosure: See Acknowledgments on page 366.

PII: S1083-8791(09)00496-0

doi: 10.1016/j.bbmt.2009.10.025

Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 358-367 , March 2010

Article Tools

* Image Usage & Resolution